Harmony Biosciences Holdings, Inc. (HRMY)

In the past six months, Harmony Biosciences' stock price has fluctuated. The stock experienced a drop after the company reported its Q1 2026 earnings, despite a year-over-year increase in net product revenue. The company participated in healthcare conferences and appointed a new CFO and board members. Harmony Biosciences has been involved in patent litigation to protect its pitolisant franchise, including filing a new patent infringement lawsuit and settling with ANDA challengers.

Harmony Biosciences experiences demand seasonality for its products, particularly WAKIX, with the first quarter of the year typically seeing "seasonal market access headwinds." Despite these seasonal dynamics, the company reported that Q1 2026 demand for WAKIX was higher than Q1 2025 and in line with expectations.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases and other neurological conditions with unmet medical needs. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparation Manufacturing industries. Its primary product is WAKIX (pitolisant) tablets, a first-in-class selective histamine 3 (H₃) receptor antagonist/inverse agonist, approved by the FDA for treating excessive daytime sleepiness (EDS) or cataplexy in adult and pediatric patients with narcolepsy. Harmony Biosciences also has a pipeline of investigational compounds, including BP1.15205, HBS-102, ZYN-002, EPX-100, and EPX-200, as well as Pitolisant formulations in clinical trials for various conditions.

Harmony Biosciences Holdings, Inc. is headquartered in Plymouth Meeting, Pennsylvania, United States, with sales primarily concentrated in the United States.

In the past year, Harmony Biosciences' brand reputation has been tied to its financial performance, product pipeline advancements, and efforts to protect its intellectual property. Analyst sentiment has been generally constructive, with some upward earnings revisions and a consensus "buy" rating. Events impacting its reputation include the Q1 2026 earnings miss, ongoing patent litigation, and strategic appointments to its executive team and board.

Harmony Biosciences Holdings, Inc. has significant institutional ownership, with institutions holding approximately 89.7% of the shares. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., and FMR LLC. Individual insiders hold a smaller percentage, around 0.133% of the shares.